Is Adalimumab Failing? Understanding Secondary Loss of Response & What to Do Next

Adalimumab (brand name Humira® and biosimilars) is a biologic medication commonly used to treat ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriasis, and other autoimmune conditions. For many people, it works well—sometimes dramatically reducing symptoms and improving quality of life.

But what happens if it seems to stop working?

If you're noticing worsening symptoms after initially doing well, you may be experiencing secondary loss of response to adalimumab. This is a recognized and relatively common clinical issue. The good news: there are evidence-based next steps.

Let's walk through what this means, why it happens, and what you and your doctor can do about it.

---

What Is Secondary Loss of Response to Adalimumab?

Secondary loss of response to adalimumab occurs when:

• The medication worked initially
• Symptoms improved or remission was achieved
• But over time, symptoms return or worsen

This is different from primary non-response, where the drug never worked in the first place.

Secondary loss of response can happen months or even years after starting treatment. It does not mean you've done anything wrong—and it doesn't mean you're out of options.

---

How Common Is It?

Clinical studies show that:

• Up to 30–40% of patients may experience secondary loss of response over time
• Rates vary depending on the disease being treated
• It is particularly studied in inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease

Because biologics target specific immune pathways, the body's response can shift over time.

---

Why Does Secondary Loss of Response Happen?

There are several well-understood reasons:

1. Anti-Drug Antibodies (Immunogenicity)

Your immune system may start recognizing adalimumab as "foreign" and produce anti-drug antibodies.

These antibodies can:

• Neutralize the medication
• Increase drug clearance from your body
• Lower drug levels in your bloodstream
• Reduce effectiveness

This is one of the most common causes.

---

2. Low Drug Levels

Even without antibodies, adalimumab levels may drop below the therapeutic range.

This can happen due to:

• Increased inflammation
• Faster metabolism
• Higher body weight
• Missed doses
• Injection technique issues

When drug levels fall too low, symptoms can return.

---

3. Disease Progression

Sometimes the disease changes over time.

Inflammatory conditions like ulcerative colitis can:

• Become more aggressive
• Involve new areas
• Develop complications

In these cases, the medication may no longer be strong enough to control inflammation.

---

4. Incorrect Diagnosis or Overlapping Conditions

Not all symptoms mean inflammation is back.

For example:

• Irritable bowel syndrome (IBS) can overlap with IBD
• Infections can mimic a flare
• Stress can worsen symptoms

This is why proper evaluation is essential before changing treatment.

---

Signs That Adalimumab May Be Failing

Depending on your condition, warning signs may include:

For ulcerative colitis or Crohn's disease:

• Increased diarrhea
• Blood in stool
• Abdominal pain
• Urgency
• Fatigue
• Weight loss

For rheumatoid arthritis:

• Joint swelling
• Morning stiffness
• Increased pain

If you're experiencing any of these concerning symptoms, it may be helpful to use a free AI-powered symptom checker for Ulcerative Colitis to better understand what you're feeling and prepare for your conversation with your doctor.

---

What Should You Do If You Suspect Secondary Loss of Response?

Do not stop adalimumab on your own.

Instead, schedule an appointment with your gastroenterologist or prescribing specialist. The next step usually involves objective testing, not guesswork.

---

Medical Next Steps: What Doctors Typically Do

1. Therapeutic Drug Monitoring (TDM)

This is a blood test that measures:

• Adalimumab drug levels
• Anti-drug antibodies

This helps determine:

• Is the drug level too low?
• Are antibodies present?
• Is inflammation truly active?

TDM is widely recommended in inflammatory bowel disease guidelines when secondary loss of response is suspected.

---

2. Check for Active Inflammation

Your doctor may order:

• Blood tests (CRP)
• Stool tests (fecal calprotectin)
• Colonoscopy or imaging
• Infection testing (such as C. diff)

This ensures symptoms are truly due to inflammatory disease activity.

---

Treatment Options If Adalimumab Is Failing

The right next step depends on what testing shows.

Scenario 1: Low Drug Levels, No Antibodies

If levels are low but no antibodies are detected, your doctor may:

• Increase the dose (e.g., weekly instead of every other week)
• Shorten dosing intervals

This often restores response.

---

Scenario 2: Anti-Drug Antibodies Present

If significant antibodies are detected:

• Switching to another anti-TNF medication may be considered
• Or switching to a medication with a different mechanism of action

Adding an immunomodulator (such as azathioprine or methotrexate) may sometimes reduce antibody formation, though this depends on individual factors.

---

Scenario 3: Adequate Drug Levels but Ongoing Inflammation

If drug levels are therapeutic but inflammation continues:

This suggests the disease is no longer responding to TNF blockade.

Your doctor may recommend switching to another class, such as:

• Vedolizumab (anti-integrin)
• Ustekinumab (IL-12/23 inhibitor)
• JAK inhibitors
• Other newer biologics

These medications target different immune pathways.

---

Is Switching Medications Dangerous?

Switching biologics is common in modern treatment algorithms. It does not mean your condition is "untreatable."

In fact:

• Many patients respond well to second- or third-line therapy
• Newer medications are highly targeted
• Safety monitoring is standard practice

The key is careful evaluation before making changes.

---

When Is It Urgent?

Seek immediate medical care if you experience:

• Severe abdominal pain
• High fever
• Persistent vomiting
• Signs of dehydration
• Heavy rectal bleeding
• Rapid heart rate
• Fainting

These could signal complications that require urgent attention.

Always speak to a doctor about anything that could be life-threatening or serious.

---

Can Secondary Loss of Response Be Prevented?

There is no guaranteed prevention, but risk may be reduced by:

• Taking medication consistently
• Not skipping doses
• Using correct injection technique
• Attending regular follow-up appointments
• Monitoring inflammation markers
• Early testing if symptoms change

Early action often prevents more severe flares.

---

The Emotional Side: What Many Patients Feel

When adalimumab stops working, people often feel:

• Frustrated
• Discouraged
• Worried about running out of options

These feelings are valid.

But medicine has evolved significantly. Today, there are more treatment options for ulcerative colitis and other autoimmune diseases than ever before. Secondary loss of response to adalimumab is a clinical problem with structured, evidence-based solutions—not a dead end.

---

Bottom Line

Secondary loss of response to adalimumab means the medication worked at first but is no longer controlling your disease adequately.

The most common reasons include:

• Anti-drug antibodies
• Low drug levels
• Disease progression
• Incorrect assumption of active inflammation

The solution starts with proper testing—not guesswork.

From there, doctors may:

• Adjust the dose
• Increase frequency
• Add combination therapy
• Switch to another biologic
• Change to a different drug class

If your symptoms are returning, don't panic—but don't ignore them either.

Take a few minutes to check your symptoms using Ubie's free AI-powered symptom checker for Ulcerative Colitis, which can help you organize and understand what you're experiencing before your next appointment with your doctor.

Most importantly:
If you experience severe symptoms or anything that feels life-threatening, seek urgent medical care and speak to a doctor immediately.

There are still options. The key is early evaluation, informed decisions, and ongoing partnership with your healthcare team.